Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
US-2015337029-A1 · Nov 26, 2015 · US
DNA antibody constructs for use against middle east respiratory syndrome coronavirus
US11230592B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11230592-B2 |
| Application number | US-201816651435-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 27, 2018 |
| Priority date | Sep 27, 2017 |
| Publication date | Jan 25, 2022 |
| Grant date | Jan 25, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.
First claim
Opening claim text (preview).
What is claimed is: 1. A nucleic acid molecule encoding one or more synthetic antibodies, wherein the nucleic acid molecule comprises at least one selected from the group consisting of: a) a nucleotide sequence encoding an anti-Middle East Respiratory Syncytial Coronavirus (MERS-CoV) synthetic antibody comprising the amino acid sequence of SEQ ID NO:2; and b) a nucleotide sequence encoding a fragment of an anti-MERS-CoV synthetic antibody comprising at least one selected from an anti-MERS dMAB heavy chain comprising the amino acid sequence of SEQ ID NO:5 and an anti-MERS dMAB light chain comprising the amino acid sequence of SEQ ID NO:7. 2. The nucleic acid molecule of claim 1 , wherein the one or more synthetic antibodies binds to a MERS-CoV antigen. 3. The nucleic acid molecule of claim 1 , further comprising a nucleotide sequence encoding a cleavage domain. 4. The nucleic acid molecule of claim 1 , comprising a nucleotide sequence at least 90% identical to at least one nucleotide sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:6. 5. The nucleic acid molecule of claim 1 , wherein the nucleotide sequence encodes a leader sequence. 6. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises an expression vector. 7. A composition comprising the nucleic acid molecule of claim 6 . 8. A composition comprising the nucleic acid molecule of claim 6 , further comprising a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
- C07K16/102Primary
Coronaviridae (F) · CPC title
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
DNA (RNA) vaccination · CPC title
viral · CPC title
- C07K16/10Primary
RNA viruses · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11230592B2 cover?
- Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV viru…
- Who is the assignee on this patent?
- Wistar Inst, Inovio Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/102. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).